secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-107299
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maze Therapeutics reports Q2 2025 net loss of $33.7M, cash $264.5M
------------------------------------------------------------------

- Net loss of $33.7M in Q2 2025 vs net income of $139.1M in Q2 2024 (prior year had $165M license revenue).
- Cash and cash equivalents $264.5M as of June 30, 2025 vs $196.8M at Dec 31, 2024; runway into H2 2027.
- R&D expenses increased to $28.1M in Q2 2025 from $19.5M in Q2 2024 due to clinical trial costs.
- MZE782 Phase 1 proof-of-mechanism data expected Q3 2025; MZE829 Phase 2 HORIZON data expected Q1 2026.
- No license revenue recognized in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/0000950170-25-107299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/maze-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer